We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.

Skip to main content

The Jackson Laboratory

Home

Recent Searches

Share this Post

Share on facebook
Share on twitter
Share on linkedin
Share on email

Home
Case Studies
Evidence-Based Selection of the Starting Dose in First-in-Human Clinical Trials Using Humanized Mouse Models

Evidence-Based Selection of the Starting Dose in First-in-Human Clinical Trials Using Humanized Mouse Models

Published Date May 22, 2023

Fill form to unlock content

Loading, please wait

Error - something went wrong!

Access Content

Thank you!

Loading, please wait

Error - something went wrong!

Don't miss new content. Subscribe to our monthly newsletter, JAX Pulse!

Thank you!

No Previous Flipbooks
Next Flipbook

In Vivo Evaluation of Bispecific T-Cell Engager Efficacy and Safety

Most Recent Flipbooks

over 1 year ago
In Vivo Evaluation of Bispecific T-Cell Engager Efficacy and Safety

Read Flipbook
almost 4 years ago
Case Study: Evaluation of the Anti-Tumor Efficacy of a Bispecific in Two Novel In Vivo Systems

The NSG Humanized Mouse platform is an efficient way to test bispecific antibodies, including CD3 binding bispecific. This case study highlights our recent data.

Read Flipbook
almost 4 years ago
Targeting Natural Killer Cell Activity with Humanized NSG IL-15 Mouse Model

The NEW cord blood CD34+ HSC humanized NSG-IL15 mouse enables efficacy research for compounds targeting human natural killer (NK) cell activity including antibody-dependent cellular cytotoxicity.

Read Flipbook
over 4 years ago
Zygote Editing of a NOD Mouse to Better Understand the Mechanism of Diabetes

Read Flipbook
over 4 years ago
Proficiency with Larger Knockins

Read Flipbook

Recommended for you

Return to Home

© The Jackson Laboratory